“生长激素第一股”维升药业港股上市,近三年利润持续亏损

界面
21 Mar

3月21日,维升药业-B(2561.HK)在港交所上市,成为“港股生长发育第一股”,摩根士丹利、Jefferies为联席保荐人,今日开盘,报68.80港元/股,市值78.38亿港元。维升药业本次香港IPO引入5名基石投资者,包括安科生物、园丰、Vivo Capital、药明生物、Reynold Lemkins,共认购0.72亿美元,占全球发售股份的78.5%。维升药业由丹麦药企Ascendis ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10